Veritas
Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt:
2VP), (“Veritas” or the “Company”) announces that its research arm, Cannevert
Therapeutics Ltd. ("CTL") has signed a letter of intent with the
Fundación de Investigación (FDI) in San Juan, Puerto Rico, to conduct the first
human study of CTL-X, its lead cannabis strain targeting pain.
Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt:
2VP), (“Veritas” or the “Company”) announces that its research arm, Cannevert
Therapeutics Ltd. ("CTL") has signed a letter of intent with the
Fundación de Investigación (FDI) in San Juan, Puerto Rico, to conduct the first
human study of CTL-X, its lead cannabis strain targeting pain.
The
study will be done in two stages to assess the analgesic effects of this lead
strain. The first stage will have an open label design to look at the feasibility
of two doses of CTL-X in 5 subjects while the second stage will use a
randomized, double-blind, crossover design to assess one dose of CTL-X against
a placebo control strain in 16 subjects who will be exposed to various
modalities of acute pain.
study will be done in two stages to assess the analgesic effects of this lead
strain. The first stage will have an open label design to look at the feasibility
of two doses of CTL-X in 5 subjects while the second stage will use a
randomized, double-blind, crossover design to assess one dose of CTL-X against
a placebo control strain in 16 subjects who will be exposed to various
modalities of acute pain.
No comments:
Post a Comment